GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Guardant Health Inc.
Guardant Health is a pioneer in the field of "liquid biopsy," which enables cancer detection through blood testing. Its stock price reflects the enormous potential of this technology for early diagnosis and treatment monitoring. Its chart is a history of scientific breakthroughs and a long road to commercialization.
Share prices of companies in the market segment - Cancer analysis
Guardant Health is a pioneer in the liquid biopsy segment for cancer diagnosis using blood tests. We classify it in the Cancer Analysis sector. The chart below reflects the overall trends and investment interest in this cutting-edge area of personalized medicine.
Broad Market Index - GURU.Markets
Guardant Health is a leader in liquid biopsy, developing blood tests for the early detection and monitoring of cancer. Its innovation has earned it a spot in the GURU.Markets index. The chart below compares its performance to the overall market.
Change in the price of a company, segment, and market as a whole per day
GH - Daily change in the company's share price Guardant Health Inc.
For Guardant Health, a developer of cancer diagnostic tests, the daily price change reflects the extreme volatility inherent in biotech. This sensitivity to research news and regulatory approvals is key to analyzing oncology risks and innovations on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Cancer analysis
Guardant Health, Inc. is a leader in liquid biopsy testing for cancer diagnostics. This chart highlights the extreme volatility of the biotech sector. Comparing it to GH, whose success depends on the adoption of its tests, helps understand its unique risks.
Daily change in the price of a broad market stock, index - GURU.Markets
Guardant Health is a leader in liquid biopsy, a non-invasive blood-based test for cancer detection and monitoring. The oncology diagnostics sector is extremely sensitive to clinical data. The chart below illustrates the volatility in this niche, reflecting both high expectations and risks.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Guardant Health Inc.
Guardant Health is a leader in liquid biopsy—a blood test for early cancer detection. Its year-over-year growth reflects rapid growth in testing volumes and investor confidence in the potential of its technology to revolutionize oncology.
Annual dynamics of market capitalization of the market segment - Cancer analysis
Guardant Health, Inc. is a leader in liquid biopsy, a blood-based cancer detection and monitoring technology. Its technology is transforming approaches to oncology. This chart shows how its scientific breakthroughs and efforts to commercialize early detection tests are impacting its position in the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Guardant Health, a pioneer in liquid biopsy for cancer diagnostics, is a breakthrough technology in medicine. Its stock price is not dependent on economic cycles, but is driven by the speed of physician adoption of its tests, insurance coverage, and new scientific data. This chart tells the story of the revolution in oncology.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Guardant Health Inc.
Guardant Health, a leader in liquid biopsy for cancer diagnostics, has sharp monthly fluctuations reflecting news of its test approvals, clinical trial data confirming their accuracy, and the pace of clinical adoption of this cutting-edge technology.
Monthly dynamics of market capitalization of the market segment - Cancer analysis
This chart reflects the dynamics of the molecular diagnostics sector. For Guardant, a pioneer in the field of liquid biopsy, this is the backdrop. Its movements demonstrate how its blood-based cancer detection technology is being adopted into clinical practice, representing a huge potential market.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Guardant Health is a leader in liquid biopsy, developing blood tests for early cancer detection and treatment selection. The chart below shows the overall market sentiment. Guardant's performance is driven by scientific breakthroughs, regulatory decisions, and the speed of clinical adoption of its tests, not by the market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Guardant Health Inc.
Guardant Health, a pioneer in liquid biopsy for cancer diagnostics, shares are extremely sensitive to scientific news. Weekly performance reflects the release of clinical data, regulatory decisions, and news about the introduction of its tests into clinical practice.
Weekly dynamics of market capitalization of the market segment - Cancer analysis
Guardant Health, like other companies in the molecular diagnostics sector, is dependent on overall trends in oncology and genetics. Advances in personalized medicine and insurance company decisions on test coverage are common drivers for all. The graph will show whether GH is ahead of the industry, confirming its leadership in liquid biopsy.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Guardant Health, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on clinical trial results and regulatory decisions. The chart below clearly demonstrates how GH shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
GH - Market capitalization of the company Guardant Health Inc.
Guardant Health's chart visualizes the hopes of defeating cancer through early detection. The company develops liquid biopsy tests for detecting cancer using blood tests. Its market cap dynamics reflect investors' faith in the revolutionary potential of this technology and its future commercial applications.
GH - Share of the company's market capitalization Guardant Health Inc. within the market segment - Cancer analysis
Guardant Health is a leader in liquid biopsy, developing blood tests for early cancer detection and treatment selection. Its market share in its innovation segment reflects its technological superiority. The chart below shows how the market perceives the potential of its tests to change the paradigm of cancer diagnostics.
Market capitalization of the market segment - Cancer analysis
Guardant Health develops blood-based tests (liquid biopsies) for the early detection and monitoring of cancer. The chart below shows the market capitalization of the oncology diagnostics sector. This is an assessment of an industry at the forefront of the cancer treatment revolution.
Market capitalization of all companies included in a broad market index - GURU.Markets
Guardant Health is a pioneer in liquid biopsy, a technology for cancer analysis using blood samples. The company's market capitalization reflects its potential to transform the approach to cancer diagnosis and treatment. Its share of the global healthcare market reflects investors' faith in a future where cancer can be detected and controlled early.
Book value capitalization of the company, segment and market as a whole
GH - Book value capitalization of the company Guardant Health Inc.
Guardant Health is built on scientific and technological capital. The company's book value comes from its cutting-edge laboratories equipped with DNA sequencers and its massive investments in developing liquid cancer biopsy tests. The chart below tells the story of how the company built the foundation for a revolution in cancer diagnostics.
GH - Share of the company's book capitalization Guardant Health Inc. within the market segment - Cancer analysis
Guardant Health develops cancer tests in its advanced clinical laboratories. These high-tech facilities are its key tangible asset. The S_BCap_Seg chart shows the company's control over the laboratory infrastructure in the oncology testing sector.
Market segment balance sheet capitalization - Cancer analysis
The chart shows the book value of the biotech sector. Against this backdrop, Guardant Health, a leader in liquid biopsy, appears capital-intensive. To conduct millions of tests, the company had to build large, highly automated laboratories, which constitute a significant tangible asset.
Book value of all companies included in the broad market index - GURU.Markets
Guardant Health operates cutting-edge laboratories that perform liquid biopsy testing for cancer detection. Their assets include unique diagnostic equipment and robotic systems. Compared to the entire medical industry, which can be visualized by looking at the graph, Guardant is building its most technologically advanced "diagnostic workshop."
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Guardant Health Inc.
Guardant Health's balance sheet is the value of its laboratories and cash reserves. Its market capitalization reflects its belief in its liquid biopsy technology and its potential to become the standard in cancer diagnostics. The MvsBCap_Co chart shows how many times the "dream" of early cancer detection from a drop of blood is worth compared to the company's actual assets.
Market to book capitalization ratio in a market segment - Cancer analysis
Guardant Health is a leader in liquid biopsy for cancer diagnostics. Its value lies in its unique technology and data. The chart demonstrates the enormous premium the market pays for its scientific potential and leadership in this revolutionary field, far exceeding the value of its laboratories.
Market to book capitalization ratio for the market as a whole
Guardant Health is a pioneer in liquid biopsy, developing blood tests for early cancer detection. The company's core value lies in its cutting-edge technology, data, and intellectual property. This chart clearly demonstrates why biotech companies can have enormous market valuations with relatively small book values.
Debts of the company, segment and market as a whole
GH - Company debts Guardant Health Inc.
For Guardant Health, a blood-based cancer diagnostics company, debt is a vital source of research funding. This chart shows how the company raises capital to conduct expensive clinical trials and bring new tests to market. In biotech, debt is an investment in science that can save lives.
Market segment debts - Cancer analysis
Guardant Health is a pioneer in the field of "liquid biopsy"—a blood test for early-stage cancer detection. Developing and commercializing such breakthrough diagnostic tests requires massive investments in science and clinical trials. This chart shows how the company funds its expensive research while remaining at the forefront of oncology.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Guardant Health Inc.
Guardant Health is developing blood-based tests for the early detection and monitoring of cancer. This chart shows the financial position of this innovative biotech company. Low debt and a reliance on equity are typical for companies that spend hundreds of millions on research and development in anticipation of breakthroughs and commercial success.
Market segment debt to market segment book capitalization - Cancer analysis
Guardant Health is a pioneer in liquid biopsy for cancer diagnosis and monitoring. This chart illustrates debt trends in the oncology analytics sector. It provides insight into how the company finances its cutting-edge but expensive research and commercialization of tests, and how its financial strategy compares to other biotech companies.
Debt to book value of all companies in the market
Guardant Health, a pioneer in liquid biopsy, operates at the cutting edge of science. The chart reflects the market's overall debt load. It helps understand how funding for such disruptive yet capital-intensive medical technologies depends on investors' overall risk appetite. Does capital continue to flow into the industry, even when the overall market is pessimistic?
P/E of the company, segment and market as a whole
P/E - Guardant Health Inc.
This chart shows the valuation of Guardant Health, a pioneer in liquid biopsy for cancer diagnostics. A high or negative P/E indicates that investors are not evaluating current profits, but rather the revolutionary potential of the technology. The dynamics of this valuation are directly dependent on the success of clinical trials, regulatory approval, and the pace of testing adoption in medical practice.
P/E of the market segment - Cancer analysis
This chart shows the average valuation for companies in the biotech and molecular diagnostics sector. For Guardant Health, a pioneer of liquid biopsy, this context is important. Its valuation is likely to be above average, reflecting investor confidence in the revolutionary potential of its technology for early cancer detection and monitoring.
P/E of the market as a whole
Guardant Health is a leader in liquid biopsy, a blood-testing technology for cancer detection and monitoring. The company is at the forefront of a revolution in oncology diagnostics. Its valuation, compared to this chart, reflecting market averages, appears to be a bet on a breakthrough technology capable of transforming medicine and capturing a huge market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Guardant Health Inc.
Guardant Health is a pioneer in liquid biopsy, developing tests for cancer detection and monitoring using blood samples. The company's future depends on the widespread adoption of its tests in clinical practice and reimbursement from insurance companies. This graph reflects investors' high expectations for a revolution in cancer diagnostics and the commercial success of Guardant's products.
%20P%2FE%20Guardant%20Health%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Guardant-Health-Inc.&v=1772513711794 "Chart of the company's future (projected) P/E Guardant Health Inc.")
Future (projected) P/E of the market segment - Cancer analysis
Guardant Health is a pioneer in liquid biopsy, developing blood tests for the early detection and monitoring of cancer. The company is at the forefront of the fight against cancer. This chart reflects expectations for the biotech sector, allowing us to assess how highly the market values the revolutionary potential of Guardant Health's technologies and its chances of commercial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-analysis&v=1772513711799 "Future (projected) P/E graph of the market segment - Cancer analysis")
Future (projected) P/E of the market as a whole
Guardant Health is a pioneer in liquid biopsy for cancer detection and monitoring. Their success depends on the implementation of medical innovations. Overall market optimism, as reflected in the chart, is fueling investment in advanced medical technologies. This allows Guardant Health to expand research and convince physicians and insurance companies of the value of their noninvasive tests.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513711813 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Guardant Health Inc.
Guardant Health is a leader in liquid biopsy, a blood-based testing technology for cancer detection and monitoring. This chart reflects the commercialization of this breakthrough medical technology. Revenue growth depends on increasing the number of tests performed for patients and pharmaceutical companies, as well as on securing insurance coverage, which opens access to the mass market.
Profit of companies in the market segment - Cancer analysis
Guardant Health, Inc. is a pioneer in the field of "liquid biopsy"—a blood test for cancer detection and monitoring. Profitability in this innovative sector depends on the technology's adoption in clinical practice and insurance coverage. This graph reflects the state of the industry, where enormous growth potential coexists with high research and development costs.
Overall market profit
Guardant Health is a pioneer in liquid biopsy for cancer diagnosis and monitoring. The company's technology enables cancer detection through blood testing. Its success depends on the implementation of innovations in clinical practice and is changing approaches to cancer treatment, demonstrating how biotech can grow independently of general market cycles.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Guardant Health Inc.
Guardant Health is a leader in liquid biopsy, a blood testing technology for cancer detection and monitoring. The company's revenue forecast depends on the widespread adoption of its tests in clinical practice and reimbursement from insurance companies. This chart shows analyst expectations regarding the revolution in cancer diagnostics and the commercial success of Guardant's tests.
%20profit%20of%20the%20company%20Guardant%20Health%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Guardant-Health-Inc.&v=1772513711856 "Graph of future (projected) profit of the company Guardant Health Inc.")
Future (predicted) profit of companies in the market segment - Cancer analysis
Guardant Health is a pioneer in liquid biopsy, a technology that detects and monitors cancer using blood tests. The company is at the forefront of the fight against cancer. This chart shows revenue projections for the medical diagnostics sector, reflecting how quickly Guardant's revolutionary technologies are being adopted into clinical practice.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-analysis&v=1772513711871 "Graph of future (predicted) profits of companies in a market segment - Cancer analysis")
Future (predicted) profit of the market as a whole
Guardant Health is a pioneer in the field of "liquid biopsy"—a blood test for cancer detection and monitoring. Demand for its tests depends on the introduction of innovations into clinical practice. This trend, reflecting the overall state of the economy, indirectly impacts healthcare funding. Rising forecasts create an environment in which the healthcare system can afford advanced diagnostic methods like those offered by Guardant.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513711911 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Guardant Health Inc.
Guardant Health is a leader in liquid biopsy, a blood test technology that detects tumor DNA fragments for early cancer detection. The company's revenue is growing as its tests are introduced into clinical practice. The high valuation on this chart reflects investors' high expectations for the revolutionary potential of this technology in the fight against cancer.
P/S market segment - Cancer analysis
Guardant Health, Inc. is a leading precision oncology company specializing in the development of liquid biopsy tests. Its blood tests help detect cancer early and personalize treatment. This chart reflects investor expectations for companies in the sector, providing insight into how the market values Guardant Health's breakthrough technologies.
P/S of the market as a whole
Guardant Health develops blood-based tests (liquid biopsies) for cancer detection and monitoring. The company is at the forefront of cancer diagnostics. This chart, showing average market valuations, clearly demonstrates the premium investors place on the company's revenue, whose technologies could radically change approaches to cancer treatment.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Guardant Health Inc.
Guardant Health is a pioneer in liquid biopsy testing for cancer detection and monitoring. This chart reflects investor confidence in the future commercial success of its tests. The valuation is based on expectations of widespread clinical adoption of its diagnostic products, which should lead to significant revenue growth in the future.
%20P%2FS%20Guardant%20Health%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Guardant-Health-Inc.&v=1772513712099 "The graph of the company's future (projected) P/S Guardant Health Inc.")
Future (projected) P/S of the market segment - Cancer analysis
Guardant Health is a pioneer in the field of "liquid biopsy"—a blood test for cancer detection and monitoring. This chart compares the company's future revenue expectations with its industry. It reflects investors' confidence in the revolutionary potential of Guardant's technology and the speed of its clinical adoption for early cancer detection.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-analysis&v=1772513712200 "Future (projected) P/S market segment graph - Cancer analysis")
Future (projected) P/S of the market as a whole
Overall optimism about future revenues hinges on breakthroughs in cancer diagnostics and treatment. Guardant Health, developing liquid biopsy-based tests for blood-based cancer detection, is at the forefront of this revolution. The introduction of their tests into clinical practice inspires hope and opens a huge market, spurring confidence in the growth of the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513712234 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Guardant Health Inc.
Guardant Health is a leader in liquid biopsy, a revolutionary blood-based cancer diagnostic method. The company's revenue is generated by selling its tests to oncologists, who use them to select the most effective treatment. This chart shows how the rapid adoption of this innovative technology in clinical practice is fueling the company's growth.
Sales of companies in the market segment - Cancer analysis
Guardant Health is a pioneer in liquid biopsy—a blood test for early-stage cancer detection and targeted therapy selection. This chart shows total revenue in the oncology diagnostics sector. It illustrates the revolutionary shift in medicine toward non-invasive testing methods, a market in which Guardant is actively shaping and leading.
Overall market sales
Guardant Health is a leading liquid biopsy company developing tests for cancer detection and treatment selection based on blood analysis. Demand for its innovative tests depends on their acceptance by the medical community and insurance coverage. This overall economic health chart reflects the healthcare system's ability to fund advanced diagnostic technologies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Guardant Health Inc.
Guardant Health is a pioneer in liquid biopsy—a blood test for early cancer detection and treatment selection. The company's future depends on the widespread adoption of its tests. The chart shows analyst revenue expectations, which are betting on a revolution in cancer diagnostics and the acceptance of the tests by insurance companies and physicians.
%20sales%20of%20the%20company%20Guardant%20Health%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Guardant-Health-Inc.&v=1772513712327 "Schedule of future (projected) sales of the company Guardant Health Inc.")
Future (projected) sales of companies in the market segment - Cancer analysis
Guardant Health is a pioneer in liquid biopsy, developing blood tests for early cancer detection and treatment selection. The company's success depends on the adoption of its tests in clinical practice. This chart shows projected sales for the entire oncology diagnostics sector, reflecting analysts' expectations for growth in this cutting-edge field.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-analysis&v=1772513712344 "Schedule of future (projected) sales of companies in the market segment - Cancer analysis")
Future (projected) sales of the market as a whole
Guardant Health is a pioneer in liquid biopsy for cancer diagnosis and monitoring. Demand for its tests depends on the adoption of innovations in clinical practice and insurance coverage. This graph reflects the overall economic situation, which impacts healthcare system budgets and their willingness to pay for advanced, but expensive, diagnostic technologies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513712349 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Guardant Health Inc.
Guardant Health is at the forefront of the fight against cancer, developing "liquid biopsy" tests for blood analysis. This chart illustrates the financial aspect of its mission. It reflects how successfully the company converts revenue from its innovative tests into net profit, which is critical for funding further research and development.
Market segment marginality - Cancer analysis
Guardant Health is a leader in liquid biopsy—a blood test for cancer detection and monitoring. It's a cutting-edge technology in oncology. This chart shows how efficiently the company translates its scientific advances into commercial products compared to other diagnostic companies, reflecting the potential of its tests and its control over high research costs.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company Guardant Health Inc.
Guardant Health is a pioneer in liquid biopsy, developing tests for cancer detection and monitoring using blood samples. This chart shows how the company is expanding its scientific and commercial capabilities. The growth of its team of scientists, lab technicians, and sales specialists is a direct result of the introduction of its innovative tests into clinical practice.
Share of the company's employees Guardant Health Inc. within the market segment - Cancer analysis
Guardant Health is a pioneer in liquid biopsy for cancer diagnosis and monitoring. This chart shows the percentage of leading scientists and technicians in the field of oncology diagnostics that the company employs. Its team is at the forefront of science, developing tests that are changing approaches to cancer treatment.
Number of employees in the market segment - Cancer analysis
Guardant Health, Inc. is a pioneer in liquid biopsy, developing tests for cancer detection and monitoring using blood samples. This chart shows overall employment in the oncology diagnostics sector. Its rapid growth reflects the revolution in cancer treatment methods and the enormous market potential. For Guardant, this confirms the demand for their cutting-edge technologies.
Number of employees in the market as a whole
Guardant Health is a pioneer in liquid biopsy, a blood test that detects cancer. The growth in staff in this chart reflects the revolution in cancer diagnostics. The company is actively recruiting scientists and lab technicians to develop and conduct its tests, which could change approaches to early cancer detection and treatment.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Guardant Health Inc. (GH)
Guardant Health develops liquid biopsy tests for cancer diagnostics. This chart shows that the market places a very high value on its scientific potential and technology. Its market capitalization is based on intellectual property, not physical assets. The high cost per employee reflects the value of unique developments and the expectation of future breakthroughs.
%20of%20the%20company%20Guardant%20Health%20Inc.%20(GH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Guardant-Health-Inc.-GH&v=1772513712490 "Chart of market capitalization per employee (in thousands of dollars) of the company Guardant Health Inc. (GH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer analysis
Guardant Health is a leader in liquid biopsy, a blood-based cancer detection technology. It's an R&D-intensive, IP-based business. Its value lies in its scientific platform and patents. This metric, compared to the industry average, reflects the significant premium the market pays for their technology per scientist.
%20by%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-analysis&v=1772513712496 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer analysis")
Market capitalization per employee (in thousands of dollars) for the overall market
Guardant Health, Inc. develops blood-based tests ("liquid biopsies") for cancer detection. This is at the forefront of biotechnology. Its high market valuation per employee reflects the technology's enormous potential and the value of its intellectual property. Investors are assessing future breakthroughs in cancer diagnostics, not current operations.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513712500 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Guardant Health Inc. (GH)
Guardant Health is a leader in liquid biopsy. They are developing blood tests for early cancer detection and treatment selection. This involves cutting-edge science and sophisticated laboratory diagnostics. This graph shows how much net profit (or loss, in the growth phase) each scientist and technician working on these breakthrough tests generates.
%20Chart%20Guardant%20Health%20Inc.%20(GH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Guardant-Health-Inc.-GH&v=1772513712533 "Company Profit Per Employee (in thousands of dollars) Chart Guardant Health Inc. (GH)")
Profit per employee (in thousands of dollars) in the market segment - Cancer analysis
Guardant Health (GH) is a leader in liquid biopsy (blood tests) for oncology (cancer detection, treatment selection). This chart shows the benchmark for cancer analysis (Medtech/Diagnostics). In this sector (R&D), the benchmark is negative. This reflects the burning of R&D budgets on the development and commercialization of breakthrough tests.
%20in%20the%20market%20segment%20-%20Cancer%20analysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-analysis&v=1772513712544 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer analysis")
Profit per employee (in thousands of dollars) for the market as a whole
Guardant Health (GH) is a leader in liquid biopsy. The company develops blood tests for early cancer detection and treatment selection, thereby avoiding invasive biopsies. This chart, which shows the average profit per employee across the market, helps us understand how the advanced diagnostics sector, where R&D and scientists create high added value, outperforms the average labor efficiency.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513712548 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Guardant Health Inc. (GH)
For Guardant Health, a pioneer in liquid biopsy for cancer diagnostics, this chart reflects the commercialization of cutting-edge science. The growth in revenue per employee reflects the growing acceptance of its tests by physicians and patients, as well as the efficiency of its laboratories and commercial team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Guardant-Health-Inc.-GH&v=1772513712575 "Sales chart per company employee Guardant Health Inc. (GH)")
Sales per employee in the market segment - Cancer analysis
Guardant Health specializes in "liquid biopsy"—blood tests for cancer detection and monitoring. This is a cutting-edge diagnostic. This metric reflects average revenue per employee for the segment. It helps assess how productive Guardant's team (scientists, technicians, and salespeople) is in commercializing this complex technology compared to other diagnostic companies.
Sales per employee for the market as a whole
Guardant Health (GH) is a leader in the liquid biopsy field, offering blood tests for cancer detection. It's a high-tech diagnostics business. This metric reflects the commercialization of their tests. Growing revenue per employee (including scientists and lab technicians) indicates that their innovative (and expensive) tests are increasingly being adopted in oncology, and their labs are operating efficiently.
Short shares by company, segment and market as a whole
Shares shorted by company Guardant Health Inc. (GH)
Guardant Health is a pioneer in liquid biopsy—blood tests for the early detection and monitoring of cancer. It's a revolutionary, but very expensive, technology. This chart shows how many investors are betting against the company, citing its massive losses, fierce competition (for example, with Exact Sciences), and uncertainty about the timing and scope of insurance coverage.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Guardant-Health-Inc.-GH&v=1772513712646 "Short Shares Chart for the Company Guardant Health Inc. (GH)")
Shares shorted by market segment - Cancer analysis
Guardant Health (GH) is a leader in liquid biopsy, a technology that detects cancer and tailors therapy based on blood tests. This chart shows the aggregate short position in the oncology diagnostics sector. It reflects investor skepticism about the timing of widespread adoption of these tests and concerns about insurance reimbursement levels.
Shares shorted by the overall market
Guardant Health (GH) is a leader in liquid biopsy (a blood test for cancer). This is a disruptive but still growing technology. When Short_All rises, it signals risk aversion. This pessimism causes investors to dump unprofitable growth stocks like GH in favor of profitable "defense" companies, despite their medical potential.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Guardant Health Inc. (GH)
Guardant Health is a leader in liquid biopsy (blood testing for cancer). This is a fast-growing but competitive diagnostics sector. A GH above 70 may reflect optimism about the adoption of its tests. A GH below 30 is often associated with concerns about competition or reimbursement issues with insurers.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Guardant-Health-Inc.-GH&v=1772513712681 "RSI 14 indicator chart for the company's stock Guardant Health Inc. (GH)")
RSI 14 Market Segment - Cancer analysis
Guardant Health is a leader in liquid biopsy. They develop blood tests (Guardant360) that detect cancer early and tailor treatments by analyzing tumor DNA. This graph measures the overall excitement or decline in the oncology diagnostics sector. It helps determine whether the entire segment is overheated by expectations of breakthroughs in early diagnostics.
RSI 14 for the overall market
Guardant Health is a leader in "liquid biopsy," a technology for analyzing cancer using blood samples. It's revolutionizing diagnostics. The company is in a "growth at any cost" phase. This euphoria/panic cycle is critical for the company: only during periods of market optimism are investors willing to fund unprofitable but breakthrough medical technologies. In a panic, such stocks are dumped.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GH (Guardant Health Inc.)
Guardant Health is a leader in liquid biopsy. Their tests (Guardant360) detect cancer mutations using blood tests, helping oncologists choose treatment without invasive biopsies. This chart is a collective 12-month forecast from analysts. It reflects their expectations for the volume of tests performed and advances in the development of early cancer detection tests.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GH-Guardant-Health-Inc.&v=1772513712780 "A chart showing analyst consensus forecasts for the expected stock price. GH (Guardant Health Inc.)")
The difference between the consensus estimate and the actual stock price GH (Guardant Health Inc.)
Guardant Health (GH) is a leader in liquid biopsy. Their tests (Guardant360) detect cancer and tailor treatment based on a blood test, not a tissue sample. This chart shows the valuation of this breakthrough diagnostic. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in this technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GH-Guardant-Health-Inc.&v=1772513712801 "A chart showing the difference between the consensus forecast and the actual stock price. GH (Guardant Health Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer analysis
Guardant Health is a leader in the field of liquid biopsy. The company develops blood-based tests for early cancer detection and treatment selection. This chart shows analysts' overall expectations for the cancer testing sector. It reflects whether experts believe in a liquid biopsy revolution or consider the technology immature.
Analysts' consensus forecast for the overall market share price
Guardant Health (GH) is a leader in liquid biopsy. They use blood (not tissue) to detect cancer and select treatments. This is an R&D project. Market expectations, as shown in this chart, influence them. During a recession (pessimism), payers (insurers) are reluctant to approve new, expensive tests, which slows their commercialization.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Guardant Health Inc.
Guardant Health is a leader in liquid biopsy. Their tests (Guardant360) detect cancer and tailor treatment based on a simple blood test, which is less invasive than a traditional biopsy. This chart is a bet on the future of diagnostics. It reflects the pace of their tests' adoption in oncology and the enormous, long-term potential of their tests for early cancer screening.
AKIMA Market Segment Index - Cancer analysis
Guardant Health is a pioneer in liquid biopsy; the company made a breakthrough by detecting and monitoring cancer (tumor DNA) using a simple blood test. This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does Guardant's revolutionary (blood test) technology differentiate it from the average diagnostic company?
The AKIM Index for the overall market
Guardant Health is a pioneer in liquid biopsy. Its tests (Guardant360) detect and monitor cancer using blood tests rather than tissue biopsies. This chart, reflecting the market average, is just a backdrop. It helps assess how this growth story in the protective healthcare sector compares to overall macroeconomic trends.
